Paige Stock

A Global Leader in Digital Diagnostics

Sign up today and learn more about Paige Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Paige Stock

Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The Company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of diagnostic devices positioned to drive the future of pathology, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s lightweight platform was purpose-built with pathologists to offer an intuitive user experience, minimize IT burden and costs while ensuring patient safety and data privacy. Paige’s products deliver insights to pathologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.

Funding History

February 2018$25.0M
December 2019$45.0M
April 2020$5.0M
July 2020$20.0M
January 2021$125M


Founder & Chief Scientific Officer

Thomas Fuchs


Leo Grady

Chief Business Development Officer

Carla Leibowitz

VP Engineering

Razik Yousfi

Board Member

David Castelblanco

Co-Founder & Senior Machine Learning Scientist

Peter Schüffler

Investor and Board Member

Jim Breyer

Member Board Of Directors

Asish Xavier

VP Engineering

Razik Yousfi


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: